Loading...
Market
What will be the next milestone set by Candela's C-8 in 24 hours by the end of 2024?
2
Resolution / Starting Odds
500 nautical miles in 24 hours • 25%
600 nautical miles in 24 hours • 25%
700 nautical miles in 24 hours • 25%
800 nautical miles in 24 hours • 25%
Official announcement from Candela or verified news sources
Story
Candela's Electric Hydrofoil Boat Travels 420 Nautical Miles in 24 Hours
Sep 17, 2024, 10:20 AM
Candela's electric hydrofoil boat, the C-8, has set a new milestone by traveling 420 nautical miles within 24 hours. The journey took place between Stockholm, Sweden, and the Baltic island of Aland. The C-8 utilizes innovative hydrofoil technology, allowing it to lift above the water on wings, which reduces energy consumption by 80% compared to conventional electric boats. Candela's CEO says this achievement underscores the advancements in electric transportation and highlights the potential for sustainable and efficient water travel.
View original story
Similar markets
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Secures Series A funding • 25%
Announces major partnership • 25%
Publishes groundbreaking research • 25%
Other • 25%
Successful autonomous navigation in open waters • 25%
Integration with U.S. Navy's existing systems • 25%
Completion of first production-ready ASV • 25%
Other • 25%
Completion of site investigations • 25%
Submission of application under the ADVANCE Act • 25%
Approval of application under the ADVANCE Act • 25%
No major milestone achieved • 25%
Starts production of 1,000 Starships annually • 33%
Reaches serialized production of Falcon 9's second stage • 33%
Completes construction and begins operations • 34%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
All Milestones Met • 25%
Most Milestones Met • 25%
Few Milestones Met • 25%
No Milestones Met • 25%